Cetuximab dose-escalation study in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab standard dose treatment (EVEREST)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Cetuximab; Irinotecan
- Indications Colorectal cancer
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms EVEREST
- Sponsors Merck KGaA
- 15 May 2008 Results will be presented at ASCO 2008 according to a ImClone Systems media release.
- 15 Feb 2007 Preliminary results have been reported.
- 14 Feb 2007 New trial record.